Ocugen, Inc. 8-K

What Happened

• Ocugen, Inc. filed an 8-K on May 5, 2026 reporting financial results for the quarter ended March 31, 2026 and scheduled a conference call and webcast for 8:30 a.m. ET on May 5, 2026 to discuss results and business updates. Presentation materials will be posted at www.ocugen.com.
• The company also announced pricing of a private offering of $115.0 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034 (the “Notes”), with an option for the initial purchaser to buy up to an additional $15.0 million of Notes. The offering is expected to close on or about May 7, 2026, subject to customary conditions.

Key Details

• Notes: $115.0M aggregate principal, 6.75% interest, due 2034; initial purchaser option up to $15.0M; offered only to qualified institutional buyers under Rule 144A.
• Estimated net proceeds: approximately $99.5M (or ~ $112.6M if option exercised in full) after discounts and fees.
• Use of proceeds: approximately $32.7M to fully repay outstanding principal, accrued interest and prepayment fees under the Avenue Loan Agreement and terminate those loan documents; remaining proceeds for general corporate purposes.
• Earnings release materials and pricing press release are included as Exhibits to the 8-K.

Why It Matters

• The convertible note financing provides Ocugen with fresh capital to pay off a prior loan (reducing that obligation) and fund general corporate needs, which can affect the company’s cash runway and operations.
• Because the securities are convertible, future conversion could dilute existing common stockholders; terms and conversion price may affect dilution but were not detailed in the filing.
• The offering is private and aimed at institutional buyers and remains subject to closing conditions; investors should monitor completion of the offering and the company’s detailed quarterly results and guidance provided on the conference call and in its SEC filings.